The Development of Bisphosphonates as Drugs

Analogue-based Drug Discovery

Volumn , Issue , 2006, Pages 371-384

  Breuer, Eli ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Analogue based drug discovery; Biological activity of bisphosphonates; Biological activity of pyrophosphate; Bone related activity; Development of bisphosphonates as drugs; Miscellaneous biological aspects of bisphosphonates

Indexed keywords

EID: 84889873160     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608001.ch18     Document Type: Chapter

References (33)

1. Von Baeyer H, Hofmann K. A. Acetodiphosphorige Säure. Ber. Dtsch. Chem. Ges., 1897, 30, 1973-1978.
2. Menschutkin N. Über die Einwirkung des Chloroazetyls auf phosphorige Säure. Ann. Chem. Pharm., 1865, 133, 317-320.
3. Lecouvey M, Leroux Y. Synthesis of 1-hydroxy-1,1-bisphosphonates. Heteroatom Chem., 2000, 11, 556-561.
4. Blomen LJMJ. History of the bisphosphonates. Discovery and history of the non-medical uses of bisphosphonates. In: Bisphosphonate on bones. Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (Eds.). Elsevier, 1995, pp. 111-124.
5. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am. J. Physiol., 1962, 203, 671-675.
6. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature, 1966, 212, 901-903.
7. Fleisch H, Russell RGG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest., 1970, 1, 12-18.
8. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science, 1969, 165, 1264-1266.
9. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science, 1969, 165, 1262-1264.
10. Fogelman I, Bessent RG, Turner JF, Citrin DL, Boyce IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J. Nucl. Med., 1978, 19, 270-275.
11. Francis MD, Fogelman I. 99mTc-diphosphonate uptake mechanisms on bone. In: Bone Scanning in Clinical Practice. Fogelman I (Ed.). Springer-Verlag, 1987, pp. 1-6.
12. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 3rd edn. New York: The Parthenon Publishing Group, 1997, pp. 145-150.
13. Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (Eds.). Bisphosphonate on Bones. Elsevier Science B.V.: Amsterdam, 1995, p. 337.
14. Green JR. Cancer, 2003, 97 (3 Suppl.), 840-847.
15. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N. Engl. J. Med., 1997, 336, 558-66.
16. Golomb G, Schlossman A, Saadeh H, Levi M, Van Gelder JM, Breuer E. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo. Pharm. Res., 1992, 9, 143-148.
17. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolised to a toxic ATP analog, adenosine 5′-(bb,cc-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res., 1997, 12, 1358-1367.
18. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DF, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. USA, 1999, 96, 133-138.
19. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 3rd edn. New York: The Parthenon Publishing Group, 1997, pp. 60-62.
20. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Alendronate Once-Weekly Study Group. Aging (Milan), 2000, 12, 1-12.
21. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif. Tissue Int., 2002, 71, 103-111.
22. Schimmer R, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin. Ther., 2003, 25, 19-34.
23. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone, 2004, 34, 881-889.
24. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer J-P, Kaufman J-M, Jaeger P, Body J-J, Meunier P-J. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med., 2002, 346, 653-661.
25. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Current Pharm. Design, 2002, 8, 99-110.
26. Wagstaff AJ, Bryson HM. Phosphonoformate. Drugs, 1994, 48, 199-226.
27. Hutchinson DW. Metal chelators as potential antiviral agents. Antiviral Res., 1985, 5, 193-205.
28. Atack JR. Inositol monophosphatase inhibitors-Lithium mimetics? Med. Res. Rev., 1997, 17, 215-224.
29. Ciosek CP, Jr., Magnin DR, Harrity TW, Logan JVH, Dickson JK, Jr., Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, Mookhtiar KA, Rich LC, Slusarchyk DA, Sulsky RB, Biller SA. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol-lowering agents in vivo. J. Biol. Chem., 1993, 268, 24832-24837.
30. Martin MB, Grimley JS, Lewis JC, Heath HT, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SNJ, Docampo R Croft SL, Oldfield E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem., 2001, 44, 909-916.
31. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatol. Int., 1994, 14, 139-147.
32. Cantatore FP, Introsso AM, Carrozzo M. Effects of bisphosphonates on interleukin 1, tumor necrosis factor, and micro-2 globulin in rheumatoid arthritis. J. Rheumatol., 96, 23, 1117-1118.
33. Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, Gati I, Moerman E, Golomb G. Macrophage depletion by clodronate-containing liposomes reduce neointimal formation following balloon injury in rats and rabbits. Circulation, 2002, 106, 599-605.